These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 35023987)

  • 21. The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments.
    Webb EJD; Meads D; Eskytė I; Ford HL; Bekker HL; Chataway J; Pepper G; Marti J; Okan Y; Pavitt SH; Schmierer K; Manzano A
    Patient; 2020 Oct; 13(5):583-597. PubMed ID: 32588337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations.
    Canibaño B; Deleu D; Mesraoua B; Melikyan G; Ibrahim F; Hanssens Y
    J Drug Assess; 2020; 9(1):20-36. PubMed ID: 32128285
    [No Abstract]   [Full Text] [Related]  

  • 23. An overview of pregnancy-related issues in patients with multiple sclerosis.
    Pozzilli C; Pugliatti M;
    Eur J Neurol; 2015 Oct; 22 Suppl 2():34-9. PubMed ID: 26374512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis.
    Vaughn C; Bushra A; Kolb C; Weinstock-Guttman B
    CNS Drugs; 2018 Feb; 32(2):161-178. PubMed ID: 29508244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pregnancy and Family Planning in Multiple Sclerosis.
    Langer-Gould AM
    Continuum (Minneap Minn); 2019 Jun; 25(3):773-792. PubMed ID: 31162316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.
    Kister I; Spelman T; Patti F; Duquette P; Trojano M; Izquierdo G; Lugaresi A; Grammond P; Sola P; Ferraro D; Grand'Maison F; Alroughani R; Terzi M; Boz C; Hupperts R; Lechner-Scott J; Kappos L; Pucci E; Hodgkinson S; Solaro C; Butzkueven H
    J Neurol Sci; 2018 Aug; 391():72-76. PubMed ID: 30103975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort.
    Langer-Gould A; Smith JB; Albers KB; Xiang AH; Wu J; Kerezsi EH; McClearnen K; Gonzales EG; Leimpeter AD; Van Den Eeden SK
    Neurology; 2020 May; 94(18):e1939-e1949. PubMed ID: 32284359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The German Multiple Sclerosis and Pregnancy Registry: rationale, objective, design, and first results.
    Thiel S; Ciplea AI; Gold R; Hellwig K
    Ther Adv Neurol Disord; 2021; 14():17562864211054956. PubMed ID: 34840606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is pregnancy in MS patients safe and what is its impact on MS course? Real World evidence of 1533 pregnancies in Czech Republic.
    Hradilek P; Meluzinova E; Zapletalova O; Hanulikova P; Horakova D; Woznicova I; Pavliska L; Stetkarova I; Valis M; Stourac P; Adamkova J; Ampapa R; Vachova M; Mares J
    Mult Scler Relat Disord; 2022 Mar; 59():103391. PubMed ID: 35240415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
    Bowen J; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
    Adv Ther; 2020 Jul; 37(7):3163-3177. PubMed ID: 32436028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
    Neuberger EE; Abbass IM; Jones E; Engmann NJ
    Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks.
    Alroughani R; Altintas A; Al Jumah M; Sahraian M; Alsharoqi I; AlTahan A; Daif A; Dahdaleh M; Deleu D; Fernandez O; Grigoriadis N; Inshasi J; Karabudak R; Taha K; Totolyan N; Yamout BI; Zakaria M; Bohlega S
    Mult Scler Int; 2016; 2016():1034912. PubMed ID: 28078140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis.
    MacDonald SC; McElrath TF; Hernández-Díaz S
    Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):556-560. PubMed ID: 30834654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab.
    Razaz N; Piehl F; Frisell T; Langer-Gould AM; McKay KA; Fink K
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 33087582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Practical Considerations for Managing Pregnancy in Patients With Multiple Sclerosis: Dispelling the Myths.
    Graham EL; Bove R; Costello K; Crayton H; Jacobs DA; Shah S; Sorrell F; Stoll SS; Houtchens MK
    Neurol Clin Pract; 2024 Apr; 14(2):e200253. PubMed ID: 38585436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reproductive issues and multiple sclerosis: 20 questions.
    Carlson AK; Ontaneda D; Rensel MR; Cohen JA; Kunchok A
    Cleve Clin J Med; 2023 Apr; 90(4):235-243. PubMed ID: 37011959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disease-modifying therapy usage in patients with multiple sclerosis in France: A 6-year population-based study.
    Leblanc S; Roux J; Tillaut H; Le Page E; Leray E
    Rev Neurol (Paris); 2021 Dec; 177(10):1250-1261. PubMed ID: 34253346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years.
    Oh J; Achiron A; Celius EG; Chambers C; Derwenskus J; Devonshire V; Hellwig K; Hutton GJ; McCombe P; Moore M; Rog D; Schneider JR; Simm RF; Sousa L; Vincent SG; Chung L; Daizadeh N; Mitchell C; Compston DAS;
    Mult Scler Relat Disord; 2020 Aug; 43():102146. PubMed ID: 32498033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Rae-Grant A; Day GS; Marrie RA; Rabinstein A; Cree BAC; Gronseth GS; Haboubi M; Halper J; Hosey JP; Jones DE; Lisak R; Pelletier D; Potrebic S; Sitcov C; Sommers R; Stachowiak J; Getchius TSD; Merillat SA; Pringsheim T
    Neurology; 2018 Apr; 90(17):777-788. PubMed ID: 29686116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.